Morgan Stanley’s NeuroOne Medical Technologies NMTC Stock Holding History

Morgan Stanley’s Portfolio NMTC Stock Details NMTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.26K	Buy	2,058 +42	+2%	+$172	﹤0.01%	7157
2026 Q1	$9.39K	Sell	2,016 -2,315	-53%	-$11.1K	﹤0.01%	6966
2025 Q4	$19.7K	Buy	4,331 +2,250	+108%	+$10.2K	﹤0.01%	6699
2025 Q3	$11.1K	Sell	2,081 -158	-7%	-$773	﹤0.01%	6872
2025 Q2	$9.11K	Buy	2,239 +248	+12%	+$916	﹤0.01%	6880
2025 Q1	$10.2K	Buy	+1,991	New	+$12.6K	﹤0.01%	6792
2023 Q1	–	Sell	-450	Closed	-$3.24K	–	7795
2022 Q4	$3.24K	Buy	+450	New	+$4.03K	﹤0.01%	7255

Other funds holding NMTC

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

EIM

Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Morgan Stanley's NMTC Position: Q2 2026 in Review

Morgan Stanley increased its NeuroOne Medical Technologies (NMTC) stake by 2.1% in Q2 2026, buying an estimated $172 and bringing the position to 2,058 shares worth $6.26K. The position accounts for ﹤0.01% of the portfolio, ranked #7157.

Morgan Stanley first reported a position in NMTC in Q4 2022 and has held it in 7 quarters since. The position peaked at $19.7K in Q4 2025. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

Morgan Stanley held 2,058 shares of NeuroOne Medical Technologies worth $6.26K as of Q2 2026.
Morgan Stanley bought 42 NeuroOne Medical Technologies shares in Q2 2026, an estimated $172.
NeuroOne Medical Technologies made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7157 holding.
Morgan Stanley first reported a position in NeuroOne Medical Technologies in Q4 2022 and has held it in 7 quarters since.
Morgan Stanley's NeuroOne Medical Technologies position peaked at $19.7K in Q4 2025.
27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.